Key facts
- It has raised $4.0M; the latest was Seed Round ($700K) in May 2025.
- Notable investors include Thylacine Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Thylacine Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Thylacine Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Thylacine Bio
Developer of peptide platform designed for pandemic preparedness. The company's platform offers a range of features such as determining relevant regions of the viral envelope protein, synthesizing proprietary lipopeptides and evaluating potency and advancing the optimal candidate into production, thereby providing clients with antivirals that are potent, self-administered, and easily distributed.
- Sector
- Healthcare
- HQ
- Miami Beach, FL, United States
- Founded
- 2021
- Website
- thylacine-bio.com/
- Ownership
- Privately Held (backing)
Thylacine Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Thylacine Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Thylacine Bio in its N-PORT filings yet. We sweep new filings monthly.